80,998 Shares in Trevi Therapeutics, Inc. $TRVI Purchased by J. Goldman & Co LP

J. Goldman & Co LP acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 80,998 shares of the company’s stock, valued at approximately $1,511,000.

Other large investors also recently made changes to their positions in the company. Nan Fung Trinity HK Ltd. boosted its holdings in shares of Trevi Therapeutics by 924.2% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock worth $11,486,000 after purchasing an additional 827,875 shares during the period. F m Investments LLC acquired a new position in Trevi Therapeutics in the 4th quarter valued at approximately $3,023,000. Candriam S.C.A. purchased a new stake in Trevi Therapeutics in the 1st quarter worth approximately $9,229,000. Pictet Asset Management Holding SA lifted its position in Trevi Therapeutics by 13,507.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock worth $19,181,000 after buying an additional 1,520,754 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Trevi Therapeutics in the 2nd quarter worth approximately $28,447,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $17.95 on Wednesday. Trevi Therapeutics, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $20.22. The stock’s 50-day moving average is $18.01 and its two-hundred day moving average is $14.66. The firm has a market cap of $2.56 billion, a P/E ratio of -52.79 and a beta of 1.03.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, equities analysts expect that Trevi Therapeutics, Inc. will post -0.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TRVI. HC Wainwright boosted their price target on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, July 20th. B. Riley Financial raised their price target on Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Wall Street Zen lowered Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. BMO Capital Markets assumed coverage on Trevi Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $36.00 price objective on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 price objective on shares of Trevi Therapeutics in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $27.08.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.